

Free NARCAN® Nasal Spray for Public Libraries Program Order and Terms and Conditions Form

The Public Library identified below (herein, the "Library") hereby acknowledges and agrees the NARCAN® (naloxone hydrochloride) Nasal Spray 4mg ("NARCAN®", NDC # 69547-353-02) will be made available and distributed by Emergent BioSolutions ("Emergent") to the library free of charge under the *Free NARCAN® for Public Libraries Program*. This program is conditioned upon the undersigned completing the following certification and the Library represents and warrants to Emergent the following:

1. The undersigned is a Public Library. A Public Library is defined as a Library that is accessible by the general public, is government chartered, and funded from public sources, such as taxes.
2. The Library will only receive and use NARCAN® in accordance with all applicable laws, rules and regulations, and takes sole responsibility for their knowledge and adherence. In addition, the Library will provide to Emergent the appropriate medical license of the registered medical advisor representing the Library who is responsible for overseeing the receipt, storage and use of the product.
3. The Library is solely responsible for the proper and safe usage of the product, and training of any library personnel who administer NARCAN® and will indemnify Emergent against any and all claims regarding the receipt, storage and administration of the NARCAN® product. The library will take reasonable measures to ensure the security of the product while in its possession to prevent loss, theft or unauthorized use.
4. NARCAN® received by the Library will be for the Library's own use and the Library shall not sell or transfer NARCAN® received pursuant to the Free NARCAN® for Public Libraries Program to any non-library third party. All uses of Narcan® will be in accordance with the full prescribing information and instructions for use accompanying the product.
5. NARCAN® nasal spray received under this program is not returnable or refundable.
6. The order quantity pursuant to the Free NARCAN® Public Libraries Program is limited to **one unit (two doses) per Library**.
7. Emergent will fulfil or refuse orders, or amend the Terms and Conditions, or discontinue the Free NARCAN® for Public Libraries Program, at its sole discretion. The individual signing the Purchase Order and Terms and Conditions possesses the requisite authority to do so on behalf of the Library, and by signing below signifies that all of the information provided by the Library is true, complete and accurate.

I have read and certify to the foregoing terms and conditions:

Authorized Representative

(physician or nurse practitioner)

Randall W. Williams, MD, FACOG
Printed Name


Signature

7-24-19
Date

BW1733117 Missouri
Prescriber License # / State

Library Representative

Name of Library

Address

City, State, Zip Code

Telephone Number

Contact Person

Email

Please scan/email the signed completed form to communityprograms@ebsi.com. For questions regarding the program, please call Emergent's customer service at 844-232-7811.

Free NARCAN® Nasal Spray for Public Libraries Program Order and Terms and Conditions Form

NARCAN NASAL SPRAY INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, diarrhea, increased heart rate (tachycardia), fever, runny nose, sneezing, goose bumps (piloerection), sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may be characterized by convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product. [Click here](#)

To report SUSPECTED ADVERSE REACTIONS, contact Emergent, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.